Healthcare
Live Price
Offline$14.00
+0.00% today
1Y Change
-27.38%
Window
Jun 30, 2025 → Jun 23, 2026
Coverage: 252 bars · Jun 30, 2025 → Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CellaVision AB (publ) (CLVSF) is a Healthcare stock with a market cap of $2.88B. The stock last traded around $14.00 and down 27.4% across the available one-year price window (Jun 30, 2025 → Jun 23, 2026). Baseline metrics include revenue growth of +4.9%, EPS growth of +8.8%, a dividend yield of 2.3%. What stands out right now is revenue +4.9%, EPS +8.8%, free cash flow -5.3% with operating margin 23.7% and ROIC 13.4%. The dividend is present but secondary, with a yield around 2.3%. Valuation is more restrained than many high-expectation growth names at P/E 21.5 and price/sales 3.9. Stock Foundry combines CLVSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
CLVSF is 46.12 pts behind over the shared 1Y window.
CLVSF had 20.90 pts deeper max drawdown than SPY.
CLVSF beat SPY in 0 of 2 calendar years shown and trailed in 2.
CLVSF
-27.38%
Normalized return
SPY
+18.73%
S&P 500
Excess Return
-46.12 pts
Relative to SPY
CLVSF Max Drawdown
-30.03%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for CLVSF and SPY.
| Year | CLVSF | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -16.80% | +6.71% | -23.50 pts | SPY |
| 2025 | -12.73% | +11.19% | -23.92 pts | SPY |
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$565.6M
-11.5% YoY
FY Net Income
$125.3M
+5.9% YoY
Free Cash Flow
$75.4M
+11.1% YoY
Revenue Growth
+4.9%
EPS Growth
+8.8%
Gross Margin
68.0%
Net Margin
18.4%
Income statement
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 759M | 723M | 677M | 639M | 566M |
| Gross Profit | 520M | 487M | 463M | 438M | 392M |
| Operating Income | 202M | 178M | 167M | 158M | 163M |
| EBITDA | 237M | 220M | 207M | 191M | 194M |
| Net Income | 153M | 141M | 130M | 118M | 125M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 188M | 149M | 122M | 108M | 130M |
| Total Assets | 1.1B | 1.0B | 929M | 892M | 825M |
| Total Liabilities | 207M | 196M | 212M | 250M | 282M |
| Shareholder Equity | 888M | 816M | 716M | 642M | 543M |
| Total Debt | 26M | 27M | 65M | 102M | 137M |
| Net Debt | -163M | -123M | -57M | -6M | 6M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
160M
+16.3% YoY
Capital Expenditures
84M
-21.4% YoY
Free Cash Flow
75M
+11.1% YoY
Key ratios
Gross Margin
68.0%
Operating Margin
23.7%
Net Margin
18.4%
ROE
15.4%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.